Clovis Oncology, Inc. (CLVS) on Focus After Crashing In Today’s Session

Clovis Oncology, Inc. (NASDAQ:CLVS) Logo

Investors sentiment increased to 1.75 in 2019 Q1. Its up 0.99, from 0.76 in 2018Q4. It is positive, as 15 investors sold Clovis Oncology, Inc. shares while 37 reduced holdings. 37 funds opened positions while 54 raised stakes. 48.93 million shares or 4.14% less from 51.05 million shares in 2018Q4 were reported.
Int invested in 119,000 shares or 0% of the stock. The Connecticut-based Point72 Asset Management L P has invested 0.07% in Clovis Oncology, Inc. (NASDAQ:CLVS). Farallon Capital Ltd Company accumulated 0.12% or 600,000 shares. Citadel Advsr Llc has 675,070 shares for 0.01% of their portfolio. Goldman Sachs Gru owns 567,470 shares or 0% of their US portfolio. Wells Fargo Mn, California-based fund reported 45,808 shares. Glenmede Tru Na holds 861 shares or 0% of its portfolio. Panagora Asset holds 0% or 104 shares. Sector Gamma As stated it has 1.51% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Amundi Pioneer Asset Management Incorporated reported 258,176 shares. The Ontario – Canada-based Fincl Bank Of Montreal Can has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Exane Derivatives stated it has 2,100 shares or 0% of all its holdings. Amer Interest Grp reported 30,362 shares stake. Daiwa Securities Gru, Japan-based fund reported 336 shares. Deutsche Bancshares Ag reported 243,822 shares or 0% of all its holdings.

Since December 20, 2018, it had 0 buys, and 2 selling transactions for $45,310 activity. 1,728 Clovis Oncology, Inc. (NASDAQ:CLVS) shares with value of $30,620 were sold by Rolfe Lindsey.

The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) is a huge mover today! The stock decreased 4.59% or $0.63 during the last trading session, reaching $13.1. About 1.16M shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 62.48% since June 12, 2018 and is downtrending. It has underperformed by 66.91% the S&P500.
The move comes after 6 months negative chart setup for the $694.36M company. It was reported on Jun, 12 by We have $12.05 PT which if reached, will make NASDAQ:CLVS worth $55.55 million less.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on August, 7. They expect $-1.69 earnings per share, up 12.89 % or $0.25 from last year’s $-1.94 per share. After $-1.63 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 3.68 % negative EPS growth.

Clovis Oncology, Inc. (NASDAQ:CLVS) Ratings Coverage

Among 5 analysts covering Clovis Oncology (NASDAQ:CLVS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Clovis Oncology had 9 analyst reports since February 13, 2019 according to SRatingsIntel. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Wednesday, February 27 by SunTrust. RBC Capital Markets maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Wednesday, February 27. RBC Capital Markets has “Buy” rating and $33 target. The firm earned “Buy” rating on Wednesday, February 27 by H.C. Wainwright. As per Wednesday, February 27, the company rating was maintained by Piper Jaffray. J.P. Morgan maintained the stock with “Hold” rating in Tuesday, February 26 report.

More notable recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: which released: “Why Is Clovis (CLVS) Down 21% Since Last Earnings Report? – Nasdaq” on March 28, 2019, also with their article: “Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript – Yahoo Finance” published on May 08, 2019, published: “Here’s Why Clovis Oncology Stock Jumped on Wednesday – Nasdaq” on February 27, 2019. More interesting news about Clovis Oncology, Inc. (NASDAQ:CLVS) were released by: and their article: “Notable Friday Option Activity: CARA, CLVS, TCX – Nasdaq” published on February 08, 2019 as well as‘s news article titled: “Are These The Next Biotech Buyout Targets? – Nasdaq” with publication date: January 22, 2019.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $694.36 million. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.